| Gallium-68 DOTATOC for Management of Neuroendocrine Tumors (NCT02375464) | Northwell Health | 2015-04-01 |
| Expanded Access Program With Nivolumab to Treat Melanoma (NCT02142218) | Bristol-Myers Squibb | 2014-06-01 |
| Single Subject Neratinib in Bladder Cancer (NRR) (NCT01956253) | UNC Lineberger Comprehensive Cancer Center | 2013-07-01 |
| A Single Patient IND for PD-0325901 (NCT02297802) | Sharp HealthCare | 2013-06-01 |
| CliniMACS® CD34+ Reagent System for Expanded Access Use (NCT02026934) | Joseph Antin | 2013-03-01 |
| PRESERVE-Zenith® Iliac Branch System Clinical Extended Study (NCT02571985) | Cook Group Incorporated | 2012-05-01 |
| Renal Denervation for Treatment of Resistant Hypertension in Patients With Chronic Kidney Disease (NCT01747382) | Singapore General Hospital | 2012-04-01 |
| Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment (NCT01473043) | Pfizer | 2012-03-01 |
| Stiripentol in Dravet Syndrome (NCT01533506) | Mayo Clinic | 2012-02-01 |
| Compassionate Use of Ibalizumab for the Treatment of HIV Infection (NCT02028819) | University of Colorado, Denver | 2012-01-01 |
| A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis (NCT01892202) | Hoffmann-La Roche | 2011-02-01 |
| A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer (NCT01120561) | Genentech, Inc. | 2010-05-01 |
| XL999 Administered Intravenously to a Subject With Advanced Malignancies (NCT01945164) | John Sarantopoulos | 2010-04-01 |
| UARK 2009-32 Compassionate Use Study of Carfilzomib (NCT00999414) | University of Arkansas | 2009-11-01 |
| Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma (NCT01005537) | Fred Hutchinson Cancer Center | 2009-06-01 |
| Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99 (NCT00931086) | Human Genome Sciences Inc., a GSK Company | 2009-04-01 |
| Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab (NCT00862758) | University of Oklahoma | 2009-02-01 |
| Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder (NCT01798914) | Mannkind Corporation | 2008-10-01 |
| An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) (NCT01026376) | Janssen-Cilag Farmaceutica Ltda. | 2008-06-01 |
| Treatment Use Study for Advanced Melanoma. (NCT00584493) | Pfizer | 2008-05-01 |
| Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection (NCT00547235) | Fred Hutchinson Cancer Center | 2007-09-01 |
| A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis. (NCT00493532) | Hoffmann-La Roche | 2007-06-01 |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (NCT00589030) | City of Hope Medical Center | 2007-04-01 |
| Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant (NCT00413270) | Novartis Pharmaceuticals | 2006-12-01 |
| Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia (NCT00302016) | Novartis Pharmaceuticals | 2006-01-01 |
| Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver (NCT00263978) | Emory University | 2005-11-01 |
| Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP (NCT01378546) | Louis H. Weimer, MD | 2005-05-01 |
| Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver (NCT00143546) | St. Jude Children's Research Hospital | 2003-11-01 |
| Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program (NCT00096811) | Bristol-Myers Squibb | 2003-09-01 |
| Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate (NCT00349739) | University of Iowa | 2003-01-01 |
| Atazanavir for HIV Infected Individuals: An Early Access Program (NCT00046345) | Bristol-Myers Squibb | 2002-05-01 |
| An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada (NCT00162188) | Bristol-Myers Squibb | 2001-05-01 |
| An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection (NCT00162227) | Bristol-Myers Squibb | 2000-09-01 |
| Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (NCT01373333) | The Cleveland Clinic | 1997-09-01 |
| Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease (NCT06056427) | Hope Biosciences Research Foundation | |
| Expanded Access Neoantigen Vaccine in Solid Tumors (NCT03914872) | Washington University School of Medicine | |
| Dextromethorphan Added on for the Patients With ADHD (NCT01787136) | Tri-Service General Hospital (TSGH) | |
| Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm (NCT03159858) | NYU Langone Health | |
| Tazemetostat Expanded Access Program for Adults With Solid Tumors (NCT03874455) | Epizyme, Inc. | |
| Flotetuzumab Expanded Access Program (NCT04678466) | MacroGenics | |
| Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma (NCT02416232) | GlaxoSmithKline | |
| Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC (NCT01947608) | Novartis Pharmaceuticals | |
| Expanded Access Remdesivir (RDV; GS-5734™) (NCT04302766) | U.S. Army Medical Research and Development Command | |
| Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements (NCT00642057) | Joseph Jankovic | |
| The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain (NCT01918514) | State University of New York - Upstate Medical University | |
| Expanded Access to Veliparib (NCT03123211) | AbbVie | |
| CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) (NCT05014724) | UCB Biopharma SRL | |
| Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT06028594) | Regeneron Pharmaceuticals | |
| An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD) (NCT05483322) | OrphAI Therapeutics | |
| Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (NCT03564964) | Suven Life Sciences Limited | |
| Emergency Use of OCR-002 in Acute Liver Failure (ALF) (NCT01634230) | Ocera Therapeutics, Inc. | |
| Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab (NCT04135092) | National Institutes of Health Clinical Center (CC) | |
| Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC (NCT06841874) | Nuvation Bio Inc. | |
| A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD) (NCT05624281) | Boehringer Ingelheim | |
| SARC021C: A Continuation Study of TH-CR-406/SARC021 (NCT02712567) | Sarcoma Alliance for Research through Collaboration | |
| Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI (NCT03925649) | Hope Biosciences LLC | |
| Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts. (NCT02158767) | Leland Metheny | |
| Expanded Access to Navitoclax (NCT03592576) | AbbVie | |
| Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) (NCT05238311) | Pfizer | |
| Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study (NCT00878943) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| cliniMACs HUD for T Cell Depletion (NCT02915406) | University of Miami | |
| Canakinumab MAP in COVID-19 Pneumonia With CRS (NCT04476706) | Novartis Pharmaceuticals | |
| Expanded Access to ABT-414 (NCT03123952) | AbbVie | |
| Treatment of Lambert-Eaton Syndrome With 3,4 DAP (NCT00704925) | David P. Richman, MD | |
| Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (NCT01538680) | Bayer | |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma (NCT07083479) | Elicio Therapeutics | |
| Dose-Dense Therapy in Aggressive Lymphoma (NCT00517894) | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| AMG 714 Expanded Access Program (NCT03439475) | Amgen | |
| Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment (NCT01194011) | Taipei Medical University WanFang Hospital | |
| Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial (NCT02354612) | Tracon Pharmaceuticals Inc. | |
| Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain. (NCT04711811) | Hope Biosciences Research Foundation | |
| Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) (NCT02389933) | Novartis Pharmaceuticals | |
| Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) (NCT01689376) | Bayer | |
| Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor (NCT05301972) | Bristol-Myers Squibb | |
| Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease. (NCT04772378) | Hope Biosciences Research Foundation | |
| Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options (NCT03943615) | Pfizer | |
| Compassionate Use of BYL 719 Alpelisib (NCT03941782) | New Mexico Cancer Research Alliance | |
| Study of the Effects of Photobiomodulation in Patients With Osteoarthritis (NCT03924128) | University of Sao Paulo | |
| Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease (NCT00535080) | Galderma R&D | |
| Expanded Access to ABBV-787 (NCT06439966) | AbbVie | |
| Managed Access Programs for INC280, Capmatinib (NCT04741789) | Novartis Pharmaceuticals | |
| Triheptanoin (UX007) to Treat Citrate Transporter Deficiency (NCT02500082) | Irina A Anselm | |
| EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C (NCT02097966) | Bristol-Myers Squibb | |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma (NCT02075177) | South Plains Oncology Consortium | |
| MAP to Provide Access to Nilotinib, for Patients With HES (NCT04498871) | Novartis Pharmaceuticals | |
| Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) (NCT03172455) | Impatients N.V. trading as myTomorrows | |
| Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease (NCT02596997) | Jazz Pharmaceuticals | |
| Ruxolitinib for Chuvash Polycythemia (NCT01730755) | Washington University School of Medicine | |
| Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan (NCT01777061) | Wendell Yap, MD | |
| This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic (NCT00244686) | GlaxoSmithKline | |
| Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND) (NCT05522569) | University of Miami | |
| Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (NCT02187354) | Amgen | |
| Vatiquinone Expanded Access Protocol (NCT07159139) | Medical University of South Carolina | |
| A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD (NCT04438512) | Resilient Pharmaceuticals | |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors (NCT04681248) | Leap Therapeutics, Inc. | |
| Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (NCT03492489) | Regeneron Pharmaceuticals | |
| Individual Patient Expanded Access IND to Treat Polyneuropathy (NCT04064983) | Hope Biosciences Research Foundation | |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer (NCT02985658) | University of Washington | |
| Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness (NCT04337359) | Novartis Pharmaceuticals | |
| Domperidone for Chronic Nausea and Vomiting (NCT02757534) | Yehudith Assouline-Dayan | |